Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
News|Articles|November 19, 2026

FDA Approves First RNAi Therapeutic for Generalized Myasthenia Gravis

Listen
0:00 / 0:00

Key Takeaways

  • Cemdisiran reduces complement activity by upstream suppression of C5 production via siRNA-mediated mRNA silencing, offering a mechanistic alternative to antibody-based C5 blockade in gMG.
  • NIMBLE demonstrated placebo-adjusted improvements at week 24 in MG-ADL (-2.30; p=0.0005) and QMG (-2.77; p=0.0015) with cemdisiran 600 mg every 12 weeks.
SHOW MORE

Alnylam-discovered cemdisiran, an siRNA silencing complement C5, is the first RNAi therapy approved for AChR-positive generalized myasthenia gravis.

FDA has approved cemdisiran (Livsayis) for adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive, Alnylam Pharmaceuticals announced on November 19, 2026.¹ Discovered by Alnylam and developed and commercialized by Regeneron, cemdisiran is the first RNA interference (RNAi) therapeutic approved for gMG and the seventh Alnylam-discovered RNAi therapeutic to win FDA approval in less than 9 years.¹

Key facts

  • Drug: cemdisiran (Livsayis; Alnylam, Regeneron)
  • Class: RNAi therapeutic (siRNA) silencing complement component 5
  • Indication: Adults with AChR antibody-positive generalized myasthenia gravis
  • Administration: Subcutaneous, 4 times a year
  • Trial: NIMBLE; phase 3, double-blind, placebo-controlled
  • Primary end point: MG-ADL placebo-adjusted difference -2.30 at week 24 (p=0.0005)
  • Key secondary: QMG placebo-adjusted difference -2.77 (p=0.0015)
  • Approval: FDA, announced November 19, 2026; first RNAi therapy for gMG
  • Alnylam economics: $25 million approval payment; tiered royalties up to 15%

“Livsayis began with Alnylam science, and its approval demonstrates how our innovation can ultimately reach patients through both our own portfolio and strategic partnerships,” said Yvonne Greenstreet, MD, CEO of Alnylam, in a company press release.¹

How does cemdisiran work for myasthenia gravis?

In AChR antibody-positive gMG, activation of the complement system contributes to damage at the neuromuscular junction.¹ Cemdisiran is a small interfering RNA (siRNA) medicine designed to reduce production of complement component 5 (C5) by silencing the messenger RNA that encodes the protein.¹ It is administered subcutaneously 4 times a year.¹

That mechanism sets cemdisiran apart from the antibody-based C5 inhibitors used in gMG, which bind the C5 protein itself rather than suppressing its production. The FDA approved one such therapy, the dual-binding nanobody gefurulimab (Klygefa), for AChR antibody-positive gMG earlier in November 2026.²

What are the results of the NIMBLE trial for cemdisiran?

The NIMBLE trial, published in The Lancet in May 2026, was a double-blind, randomized, placebo-controlled phase 3 study in adults with generalized myasthenia gravis.³ Cemdisiran 600 mg given subcutaneously every 12 weeks produced a placebo-adjusted difference of -2.30 in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score at week 24, the primary end point (p=0.0005; n=64 vs 59 for placebo).⁴ Mean MG-ADL change was -4.52 with cemdisiran and -2.22 with placebo.⁴ On the Quantitative Myasthenia Gravis (QMG) scale, a key secondary end point, the placebo-adjusted difference was -2.77 (p=0.0015), with mean changes of -4.24 and -1.46.⁴ The trial also tested a fixed-dose combination of cemdisiran and pozelimab given every 4 weeks, which showed a placebo-adjusted MG-ADL difference of -1.74 (p=0.0086); the published results report no additional benefit from adding pozelimab.³,⁴

Treatment-emergent adverse events occurred in 69% of cemdisiran-treated patients and 77% of those receiving placebo, with serious events in 3% and 14%, respectively.⁴ No meningococcal infections were reported in the cemdisiran group, and no patients in that arm discontinued because of adverse events through week 24.³,⁴

What does Alnylam receive?

Alnylam will receive a $25 million payment for the approval and is eligible for tiered, double-digit royalties of up to 15% on global net sales.¹ Alnylam scientists discovered the molecule and advanced it into phase 2 development before it became part of an RNAi collaboration with Regeneron.¹ In 2024, Regeneron assumed sole responsibility for development, manufacturing, and commercialization.¹

Why does this approval matter for RNAi?

RNAi is a cellular gene-silencing process whose discovery was recognized with the 2006 Nobel Prize in Physiology or Medicine.¹ siRNA molecules act upstream of conventional medicines by silencing the messenger RNA that encodes disease-associated proteins, preventing those proteins from being made.¹ Alnylam said in its release that RNAi therapeutics have treated hundreds of thousands of patients worldwide.¹

What are the limitations?

The release does not summarize the clinical data supporting the approval, describe the approved label, or report adverse reactions or warnings. Complement inhibitors as a class carry infection risk that the release does not address. The individual trial figures cited this article come from Regeneron's own announcement rather than the published paper. NIMBLE compared cemdisiran with placebo rather than with approved gMG therapies, so relative efficacy is unknown, and the placebo-controlled period ran 24 weeks, leaving longer-term outcomes undefined. Royalty rates depend on future sales.

References

  1. Alnylam Pharmaceuticals. Alnylam collaborator Regeneron secures FDA approval of Livsayis (cemdisiran), the seventh FDA-approved therapeutic from Alnylam's RNAi platform in less than nine years. Press release. Published November 19, 2026. Accessed November 19, 2026. https://investors.alnylam.com/press-release?id=10d98b15-1f66-4478-a56b-acc5dfc93feb
  2. AstraZeneca. Klygefa (gefurulimab) approved in the US for the treatment of generalised myasthenia gravis (gMG) in adult patients. Press release. Published November 16, 2026. Accessed November 19, 2026. https://www.astrazeneca.com/media-centre/press-releases/2026/klygefa-gefurulimab-approved-in-the-US.html
  3. Vu T, Habib AA, Jacob S, et al; NIMBLE Trial Investigators. Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomized, placebo-controlled, phase 3 trial. Lancet. 2026;407(10540):1712-1725. doi:10.1016/S0140-6736(26)00690-2
  4. Regeneron Pharmaceuticals. Regeneron announces positive results from phase 3 trial in generalized myasthenia gravis. Press release. Published August 26, 2025. Accessed November 19, 2026. https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-positive-results-phase-3-trial-generalized

Related to this article